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Oxidative stress is an important component of various diseases. It manifests as 
an imbalance caused by an excessive production of reactive oxygen species (ROS) 
which are associated with a deficit of antioxidant activity. This deficit can be the 
consequence of genetic factors, environmental ones, metabolic imbalance, toxicity 
or direct attacks by the accumulation of free radicals. These can induce metabolic 
dysfunction affecting biological macromolecules in their structures or activities. 
From a physiological perspective, the neutralization of free radicals is ensured by 
enzymatic, antioxidant and non-enzymatic defense systems. In the present chapter, 
we will focus on the endogenous enzymatic antioxidant defense system such as 
superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPxs), thio-
redoxin (Trx) and paraxonase which play an important role in homeostatic redox 
balance. Also, we will review this set of antioxidants enzymes within different 
pathological states such as diabetes, cancer, autoimmune diseases, cardiovascular, 
Alzheimer’s, Parkinson’s or parasitic diseases such as Leishmaniasis and Malaria.
Keywords: oxidative stress, antioxidant defense, ROS, enzymatic antioxidant, 
pathology
1. Introduction
Oxidative stress is defined as an imbalance between the production of reactive 
oxygen species (ROS) and cellular antioxidant capacities. ROS have long been con-
sidered toxic by-products of normal oxygen metabolisms and they are implicated in 
various pathologies. Yet, their controlled production is an essential mechanism of 
cell signaling that participates in the maintenance of cell homeostasis [1].
As a concept in redox biology and medicine, Oxidative stress was formulated in 
1985 [2]. Currently, as of late 2020, approximately 14,216 publications are presented 
for the term oxidative stress and 3,775 are associated with the term antioxidant 
defense in PubMed. An important component of various diseases, oxidative stress 
can also be said to be the result of a biological inability to detoxify reactive interme-
diates [3]. A large number of methods, such as DNA oxidation, have been developed 
and used in almost all diseases to measure its extent and nature. Findings confirm 
the fact that the paradox of ROS, as these are both toxic products of metabolism, 
and molecules essential for cell signaling and regulation. A moderate and controlled 
production of ROS can lead to a reversible oxidation of the surrounding molecules. 
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In such a case, ROS act as correct second messengers. Conversely, an overproduction 
of ROS or a deficit in defense mechanisms can lead to the appearance of stress which 
causes non-specific and irreversible oxidation of biological molecules, engendering 
dysfunction [1, 4]. The production of free radicals occurs continuously in cells as a 
result of common metabolic processes. However, at high concentrations, whether 
from endogenous pathological stimuli (hyper-LDLemia, hypertension, diabetes, 
etc.) or exogenous sources (environmental pollutants, smoking, etc.), they can lead 
to cell death and disease states via the deterioration of molecular and cellular con-
stituents of the arterial wall [5]. Such a stress can be limited by antioxidant systems, 
followed by a rapid return to a physiological redox state. It can also be prolonged, 
resulting in the creation of a new redox balance of a higher and permanent oxidizing 
level, similar to the one that can be found in chronic pathologies [6].
It is well established that oxidative stress is the main pathophysiological compo-
nent of many human or animal. It participates in pathogenesis as well as the inflam-
mation with which it is often associated. In several serious diseases, especially those 
related to aging, oxidative stress is often the original triggering factor. This is the 
case for cancers, eye pathologies (cataracts and macular degeneration), neurode-
generative diseases (ataxias, lateral sclerosis, Alzheimer’s disease). Familial amyo-
trophic lateral sclerosis is the most illustrative example, since it is caused by a defect 
in the antioxidant enzyme superoxide dismutase gene. In other diseases, oxidative 
stress plays only a secondary role in the onset of the pathology, but participates 
nonetheless in immune or vascular complications. This is the case for infectious dis-
eases such as AIDS, septic shock, diabetes, Parkinson’s disease or kidney failure [7]. 
This is also the case with parasitic diseases. Studies suggest the hypothesis that cel-
lular environments, lifestyle, genetic factors (genetic polymorphism) and metabolic 
state such as hyperglycemia are stimulants that trigger stress. They have shown that 
when the antioxidant defense is diminished or absent, the biological environment 
can no longer counter or adapt to the new physiological situation, and a cascade 
of ROS production reaction is triggered inducing both immune and metabolic 
imbalance, as well as structural and functional altercations of proteins involved 
in antioxidant defense. In the present chapter, we are interested in elements of the 
endogenous enzymatic antioxidant defense system, such as superoxide dismutase 
(SOD), catalase (CAT), glutathione peroxidase (GPxs), thioredoxin (Trx) and 
paraxonase which play a role important in the homeostatic redox balance. We will 
discuss the association of endogenous enzymatic defense with certain pathologies 
such as neurodegenerative diseases, autoimmune diseases such as diabetes, cancer, 
cardiovascular diseases, parasitic diseases.
2. Antioxidant defense mecanisms
The production of free radicals in living systems is continuous [8]. Oxygen  
(or dioxygen, O2) is an essential gas to life. It can become reactive, forming superox-
ide (O2 
● −). It is likely to cause damaging effects in the human body via the forma-
tion of free radicals and reactive oxygen species (ROS) [9]. These are much more 
toxic than oxygen itself [10]. However, O2 toxicity and “free radical theory” has 
already been proposed in the literature to explain the aging process [11].
Antioxidant enzymes play a key role in detoxifying free radicals and reducing 
oxidative stress. They are the basis of the scavenging of reactive oxygen species 
(ROS)[12].
Electrons released by the mitochondrial electron transport chain (Mito-ETC) 
and produced by NADPH oxidases (NOX) are the main source of endogenous 
3
Endogenous Enzymatic Antioxidant Defense and Pathologies
DOI: http://dx.doi.org/10.5772/intechopen.95504
reactive oxygen species. Coupled with molecular oxygen, they give rise to the pri-
mary free radical and the precursor of the remaining species - superoxide (O2
● −).  
When in reaction with a short-lived nitric oxide (NO●), the superoxide forms a 
highly reactive peroxynitrate (ONOO−) capable of modifying the structure and 
function of proteins. Superoxide dismutase (SOD) converts superoxide to hydro-
gen peroxide (H2O2), which can be converted in several ways. In the presence of 
transition metal ions like Fe2+ (Fenton reaction) or in the context of a reaction 
with superoxide, H2O2 forms a highly reactive hydroxyl radical (OH
●) which 
damages lipids, proteins. DNAHydrogen peroxide (H2O2) can also be implicated 
in the oxidation reaction of monomeric glutathione (GSH) to glutathione disul-
fide (GSSG), or that of reduced thioredoxin (Trx red) to oxidized thioredoxin 
(Trx ox) catalyzed by glutathione peroxidase (GPX) or peroxidases involved in 
the renewal of thioredoxin (Trx). The reduced glutathione pool is restored by 
glutathione reductase (GR) which reduces oxidized glutathione via the use of 
NADPH. Thanks to the thiol groups in the cysteine (Cys) residues, glutathione 
and thioredoxin participate in the reduction of oxidized proteins. Their synthesis 
and renewal take place under tight homeostatic control creating a system respon-
sible for the reduction of proteins sensitive to oxidation–reduction in the event of 
oxidative stress (Figure 1). Permeable H2O2 is involved in the signaling process 
and is degraded by catalase, glutathione peroxidase and peroxiredoxin3. Efficient 
regulation of mitochondrial H2O2 via endogenous antioxidant pathways is there-
fore an essential mechanism for maintaining physiological redox signaling and 
homeostasis [13, 14].
The mitochondria is not only one of the main sources of intracellular ROS, it is 
above all the main target. ROS can have a direct effect on mitochondrial activity. An 
induced alteration of mtDNA can alter the functioning of the respiratory chain and 
Figure 1. 
Defense mechanisms of antioxidants. e-: electron; GPxs: glutathione peroxidase, GR: Glutathione reductase, 
GSH: Glutathione, GSSG: Glutathione disulfide ; H2O2 : Hydrogen peroxide, iNOS: nitric oxide synthase; LDL: 
low density lipoprotein; NO● : Nitric oxide ; NOS : nitricoxide synthase ; NOX: NADPH oxidases; NADP: 
Nicotinamide Adenine Dinucleotide Phosphate; O2: Dioxygen; O2 
● − : Superoxide anion; OH●: Hydroxyl 
radical; ONOO●: Peroxynitrite; ONOOH: Peroxynitrite acid; PON: Paraxonase; ROS: reactive oxygenated 
species; SOD: superoxide dismutase; Trx ox: oxidized thioredoxin ; Trx red: reduced Thioredoxin ; Trx: 
thioredoxin; Cu: copper Fe: iron; Zn: zinc; Mn: manganese;Vit: vitamin.
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trigger a vicious cycle that increases ROS production and oxidative mitochondrial 
damage. Likewise, increased oxidation of mitochondrial membrane phospholipids 
could alter mitochondrial function [15].
3. Endogenous antioxidant enzymes
3.1 Superoxide dismutases
Superoxide dismutase (SOD) is a metalloprotein, representing one of the first 
lines of defense against the deleterious effects of free radicals. Thus, SODs are able 
to eliminate the superoxide anion O2
•− by a disproportionation reaction, forming, 
with two superoxides, one molecule of oxygen and one molecule of hydrogen per-
oxide H2O2. In humans, 3 isoenzymes are described: cytosolic SOD1 (Cu/Zn-SOD), 
mitochondrial SOD2 (Mn-SOD) and extracellular SOD3 (Cu/Zn-SOD) [9, 16, 17]. 
These different forms of SOD elicit similar functions, but the characteristics of their 
quaternary protein structures, their chromosomal locations, their requirements for 
metal cofactors, their gene distributions and their cellular compartmentalisation 
are different from one another [18, 19].
SOD1, or CuZn-SOD (EC 1.15.1.1) was the first enzyme to be characterized. It 
consists of a copper and zinc-containing homodimer found almost exclusively in 
intracellular cytoplasmic spaces [20]. The SOD2, or Mn-SOD (EC 1.15.1.1), exists 
in the form of a tetramer containing manganese. It is a 222 amino acid protein 
with an N-terminal signal sequence of 24 amino acids. This enzyme is found 
exclusively in the mitochondrial matrix [21]. SOD3, or EC-SOD (EC 1.15.1.1), 
is a tetramer containing copper and zinc. It is found exclusively in the extracel-
lular spaces. It is secreted by smooth muscle cells and constitutes the major 
antioxidant system of the arterial wall: its expression and secretion are increased 
by vasoactive factors (histamine, endothelin 1, angiotensin II) and decreased by 
homocysteine [9].
3.2 Catalase
Human catalase [CAT; EC 1.11.1.6] is an endogenous antioxidant enzyme 
of approximately 60 kDa. Its protein structure takes the form of a tetramer 
composed of a complex of 4 identical subunits, each containing 527 amino acid 
residues and a heme group with Fe3
+ [22, 23]. Catalase has been mapped on 
chromosome 11p13. It converts the hydrogen peroxide “H2O2” of reactive oxygen 
species into water “H2O” and oxygen “O2” thus reducing the toxic effects of 
hydrogen peroxide [24].
3.3 Glutathion peroxydase
Glutathione peroxidases (GPx; EC 1.11.1.19) are a family of phylogenetically 
related oxidoreductases distributed in all living domains. GPx is a tetrameric 
selenoprotein, containing seleno-cysteine (Sec) in the active site [25]. It catalyzes 
the reduction of organic hydroperoxides (-ROOH) into alcohol and water groups 
using reduced glutathione (GSH) as a cosubstrate. It can also catalyze the reduction 
of hydrogen peroxide (H2O2) to H2O and oxygen by oxidation of GSH reduced to 
its disulfide (GSSG). Oxidized glutathione (GSSG) can be reduced to GSH by the 
enzyme GSH reductase (GR), via the use of NADPH as a reducing substrate [26, 27]. 
Thus, GPxs protect against oxidative damage and are involved in the detoxification 
of hydrogen peroxide [28].
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3.4 Paraxonase
The paraoxonase (PON) (EC:3.1.1.2) gene family includes three proteins, PON1, 
PON2 and PON3. PON1 and PON3 are both associated with high density lipoprotein 
(HDL) particles and exert anti-oxidant and anti-inflammatory properties [29]. The 
PON gene is located on the long arm of chromosome 7 in humans [30, 31]. PON 
proteins are all associated with high density lipoprotein (HDL) particles and exert 
anti-oxidant, anti-inflammatory and lipo-lactonase activities [29]. All PON proteins 
are involved in the pathogenesis of several inflammatory diseases including athero-
sclerosis, Alzheimer’s disease, Parkinson’s disease, diabetes and cancer. PON1 is found 
exclusively extracellular and associated only with high density lipoprotein (HDL) 
particles in the circulation, and partly confers the anti-oxidant and anti-inflamma-
tory properties associated with HDL. Studies have shown that intracellular PON pro-
teins; PON2 and PON3 are associated with mitochondria and membranes associated 
with mitochondria, modulate mitochondria-dependent superoxide production and 
prevent apoptosis. In addition, it has been shown that the overexpression of the PON2 
and PON3 genes protects the mitochondria from mitochondrial dysfunction [31].
3.5 Thioredoxine
The thioredoxin (Trx) system is one of the central antioxidant systems in mam-
malian cells, maintaining a reducing environment by catalyzing the flow of elec-
trons from nicotinamide adenine dinucleotide phosphate to Trx reductase in Trx, 
which reduces its target proteins using highly conserved thiol groups. Thioredoxin 
(Trx) is a 12 kD oxidoreductase enzyme containing a dithiol-disulfide active site. 
It is ubiquitous and found in many organisms, from plants and bacteria to mam-
mals. It is located on chromosome 9 in the cytogenic position 9q31.3 [32]. The redox 
cascade of the Trx system is initiated by NADPH+. H+ is generated by the pentose 
phosphate pathway. NADPH+H+ reduces oxidized Trx reductase (TrxR), which 
regenerates the pool of reduced Trx. Reduced Trx helps maintain a reducing envi-
ronment for a number of different proteins [33]. In mammalian cells, there are two 
isoforms of Trx, a cytosolic Trx1 isoform which under certain circumstances can be 
transferred into the nucleus and secreted out of the cell, and the mitochondrial iso-
form Trx2. Unless explicitly stated otherwise. There is also a truncated form of Trx 
(Trx80) which has no redox properties and is not reduced by Trx reductase [33]. 
Trx, as an antioxidant, maintains the balance of redox status bound to thiol and also 
plays a central role in the regulation of redox signaling. Trx detects and responds to 
environmental oxidative stress1. The ROS generated by cellular respiration, metab-
olism and immune response, then modulates the redox status, function and activity 
of its target signaling proteins. Deregulation of such a Trx system affects various 
cellular functions and outcomes such as cell survival and death, leading to human 
diseases including cancer and inflammation [34]. Thioredoxin reductase (rxRs) are 
oxidoreductases necessary for the reduction of the active disulfide site in Trx and 
responsible for maintaining the pool of reduced and active Trx. Additionally, TrxR 
is a selenoprotein, and selenium is required for its expression and activity [33].
4. Pathologies
4.1 Neurodegenerative diseases
Aging is a major risk factor for several common neurodegenerative dis-
eases, including Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), 
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Alzheimer’s disease (AD) and Huntington’s disease (HD). Recent studies have 
implicated mitochondrial dysfunction and oxidative stress in the aging process 
and also in the pathogenesis of neurodegenerative diseases. In the brain and 
other tissues, aging is associated with progressive impairment of mitochondrial 
function and increased oxidative damage. Three phenomena leading to oxida-
tive stress in the brain, and implicated in neurodegenerative diseases, include 
inhibition of mitochondrial metabolism, neuronal excitotoxicity, and neuroin-
flammation [35].
4.1.1 Parkinson disease
Oxidative stress is an important factor in the Parkinson’s disease (PD) patho-
genesis. The main source of oxidative stress in the genesis of PD is the activation 
of glial cells and dopaminergic neuronal death of the substantia nigra [36, 37]. The 
oxidative imbalance involved in the neurodegenerative processes of PD appears 
to be a multifactorial phenomenon triggered by factors such as aging of the brain, 
genetic predisposition, mitochondrial dysfunction, free radical production and 
environmental toxins [37, 38]. Some studies suggest that although the accumulation 
of ROS plays a key role in the initiation and acceleration of cell death in PD, it is not 
the only cause of cell death in this disorder [39].
The activities of SOD, CAT, glutathione peroxidase (GSH-Px) and glucose-
6-phosphate dehydrogenase (G6PD) have been reported to be significantly lower 
in patients with PD [36, 37]. The production of superoxide has also been found 
to increase considerably when the flow of electrons is inhibited at the level of the 
mitochondrial complex I or III complex [35, 40, 41].
4.1.2 Alzheimer’s disease
Oxidative stress plays a role in Alzheimer’s disease (AD), an age-related multi-
factorial disease leading to loss of cognitive functions [42]. It is characterized by a 
loss of synapses, an increase in the number of senile plaques (SP) and extracellular 
amyloid rich in beta-peptide (Aβ). Metal ions can bind to beta amyloid peptide 
(Aβ) to produce ROS. Thus, the damaged Aβ during the production of ROS, causes 
cellular toxicity and oxidation of neuronal membrane biomolecules and leads to 
disruption of membrane integrity [43]. It has been reported that oxidative stress 
may play a role in the pathogenesis of dementia AD and cerebral ischemia that 
causes vascular dementia (DV) [43]. The presence of early oxidative damage in mild 
cognitive impairment in amnesia (aMCI) has been shown to exist before clinical 
dementia in AD develops [44].
It has been reported that the neurodegenerative process of this disease is linked 
to a cyclical process between impaired energy metabolism, associated with lactate 
production and oxidative stress. Indeed, a decrease in complex IV activity and mito-
chondrial DNA mutations has been identified in patients with AD [40]. In addition, 
oxidative stress may be an early event in AD etiology, since markers of oxidation 
appear in mild cognitive impaired regions of the brain [42]. A strong association 
between low serum CAT, SOD, GPx and PON1 activity and the risk of AD has been 
reported.
4.2 Cardiovascular diseases
Cardiovascular disease is a group of disorders affecting heart and blood vessels. 
In a physiological state, ROS are modulators of signal transduction pathways and 
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gene expression involved in vascular homeostasis. The cells of the vascular wall 
exhibit a physiological redox state that can be disrupted under many pathophysi-
ological circumstances, causing oxidative stress that is deleterious to the cells 
concerned and their vascular functions. The causes of this imbalance are multiple, 
and overlap at least partially the classic cardiovascular risk factors: arterial hyper-
tension, hypercholesterolemia, diabetes, etc. These risk factors are at the origin of 
stimuli responsible for an abnormal production of ROS, in particular by activation 
of NADPH oxidases and of the mitochondrial respiratory chain, a decrease in the 
bioavailability of NO to vasodilator effects. The pro-oxidant imbalance leads to the 
formation of oxidized LDL and multiple cell dysfunctions: release of pro-inflam-
matory factors and factors promoting cell proliferation, process of apoptosis and/or 
necrosis [6].
Several causes can produce an oxidative alteration which ultimately affects 
gene expression. Extracellular signals (cytokines emitted during inflammation, 
for example) are transmitted at the membrane level by receptors. These activate 
oxidases, thus generating H2O2, which acts as a second messenger. Likewise, an 
influx of xenobiotics can activate oxidative metabolism and lead to an overproduc-
tion of H2O2. The resulting modification of the “intracellular redox potential” will 
modulate the activity of certain transcription factors, and lead to a modification of 
gene expression [45] which as a result is partly responsible for the lowering of the 
defense of antioxidant enzymes.
4.3 Auto-immune diseases
Autoimmune disease is a pathological condition characterized by the break-
down of the self-tolerance of the immune system in the body in which genetic and 
environmental factors are involved. Immunological processes against tissues and 
organs lead to increased oxidative stress, and in turn, an imbalance of oxidative 
stress worsens the pathobiology of the disease. This is for example the case in type1 
diabetes, multiple sclerosis or rheumatoid arthritis, systemic lupus erythematosus 
(SLE) and Sjögren syndrome (SS) [46]. Here, we will look at the oxidative stress 
and antioxidant defense relationship in type 1 diabetes (T1D).
T1D is a multifactorial disease and results from the destruction of insulin-
secreting beta cells induced by an autoimmune process [47] with a strong inflam-
matory component [48]. Usually T1D is triggered by individuals with a specific 
genetic predisposition [49]. It is now clear that environmental factors play an 
important role in the development of this disease [50]. T1D involves the generation 
of pro-inflammatory cytokines and reactive oxygen species (ROS) [1]. The genera-
tion of free radicals potentiates the pathogenesis by promoting the destruction of 
cellular components, tissue damage and inflammation [51].
There is an inherent association with stress and the synthesis of reactive 
oxygen species (ROS) by immune cells to directly induce the destruction of B 
cells in the pancreas. However, recent evidence has shown that ROS can not only 
function as effector molecules involved in the pathogenesis of pancreatic β cells, 
but can also promote activation of innate and adaptive immune pathways in T1D 
[52]. Several previous studies have shown that hyperglycemia is associated with a 
decrease in oxidative defense. This confirms the hypothesis that hyperglycemia is 
at the origin of the production of reactive species and the decline in antioxidant 
defense [53, 54]. On the other hand, another study, carried out on endothelial cells 
of human origin, shows that high concentrations of glucose increase the activities 
of anti-oxidant enzymes (SOD, catalase, glutathione-peroxidase) as well as their 
cellular overexpression. This is evidence of an oxidative stress response resulting 
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from high glucose levels [55]. It has been reported in poorly balanced diabetic 
patients that erythrocyte SOD is often reduced when the glycation level is high. 
This results in a reduction of enzyme’s activity. Experimental evidence has shown 
that exposure to high concentrations of hydrogen peroxide can damage beta cells 
in the pancreas [56].
4.4 Cancer
It is becoming increasingly evident that ROS play an important role in the biology 
of tumorigenesis. Cancer cells increase ROS production to activate localized pro-
tumorigenic signaling, and balance the increase in ROS with high antioxidant activity 
to maintain redox balance. Nevertheless, mutations associated with different types 
of cancer are often cited as the cause in the increased production of ROS. Hypoxia, 
activation of oncogenes, mutations in mitochondrial DNA, and loss of tumor 
suppressors have all been shown to lead to increased mitochondrial ROS-dependent 
tumorigenesis. Several tumor suppressors such as the “guardian of the genome” P53 
have been shown to have ROS inhibitory functions. In about 50% of cancers, the 
tumor suppressor p53 is lost or mutated [57].
Several studies have shown that there is a strong relationship between inflam-
mation, oxidative stress and cancer. The evolution of tumor metastases depends on 
an oxidative environment and inflammation, thus contributing to long-term cell 
damage and promoting carcinogenesis. Alterations in PON status encompassing 
genotype, activity and/or expression have been demonstrated in cancer patients, as 
well as in various cancer cells in vitro [58]. In recent years, overexpression of PON2 
and PON3 has been observed in cancer cells and it has been proposed that both 
enzymes may be involved in tumor survival and resistance to stress. In addition, a 
lower activity of serum PON1 has been reported in cancer patients [58, 59]. Huang 
et al. found that PON3 is involved in multi-drug resistance in esophageal cancer 
(CE). Drug resistance prevents effective treatment of cancers [60]. As a result, 
blocking the antioxidant defense in tumors decreases their ability to balance oxida-
tive stress and results in cell death [61]. Indeed, several clinical studies on several 
types of cancer have reported low levels of activity of antioxidant enzymes such as 
SOD, GSH and CAT in groups of patients with prostate cancer [62], breast cancer 
[63] et malignant lymphoma in children [64]. Also, another study showed that 
MCF-7 breast cancer cells chronically exposed to ascorbate/menadione become 
resistant (Resox cells) by primarily increasing catalase activity. These data suggest 
that chromatin remodeling is a major regulatory process controlling the expres-
sion of catalase in breast cancer cells when developing resistance to oxidative 
stress [65].
4.5 Parasitic diseases
Infectious diseases are often associated with oxidative stress and an inflam-
matory response. Infection and inflammation trigger a cascade of reactions in the 
host, known as the acute-phase response. Neglected diseases due to the parasitic 
protozoa Leishmania, Trypanosoma and Plasmodium affect millions of people 
worldwide, and the lack of suitable treatments has promoted an ongoing drug 
discovery effort to identify novel nontoxic and cost-effective chemotherapies. 
Leishmaniasis and Malaria are the most important neglected tropical diseases, 
with a disease burden of 0.2 to 0.4 million cases with a mortality rate of 20,000 to 
40,000 reported per year for visceral leishmaniasis [66] and 214 million cases for 
malaria in 2015 and mortality of 1 to 2 million every year [67].
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4.5.1 Oxidative stress and malaria
In response to infection caused by Plasmodium parasites, the natural host 
defense mechanism is activated with involvement of phagocytes (macrophages 
and neutrophils). These, in turn, generate large amounts of ROS and RNS, caus-
ing an imbalance between the formation of oxidizing species and the activity of 
antioxidants. This imbalance is what triggers oxidative stress, which is an important 
mechanism of human hosts in response to infections and, in the case of Malaria, can 
lead to the death of the parasites [68]. Plasmodium spp. are global pathogens with a 
complex life cycle alternating between female Anopheles mosquitoes and vertebrate 
hosts that require the formation of unique zoite forms to invade different cell types 
at specific stages. Once sporozoites enter the host, they infect hepatocytes, and this 
is followed by the asexual cycle in the blood. Sexual forms that develop during the 
blood stage are ingested by a feeding mosquito, completing the cycle [69].
Plasmodium digests hemoglobin within its acidic food vacuole and releases toxic 
ferriprotoporphyrin IX (FP) and ROS [70]. Normally FP polymerizes to hemozoin 
but can also react with O2 to form ROS, superoxide radical (O2
●−) that can be 
reduced to H2O2 by SOD. H2O2 can further be reduced to H2O by either thioredoxin-
dependent peroxidase (TPx) or GST in the parasite or by GST, TPx, GPx, and CAT 
in the host cell. ROS can react with lipids and proteins forming oxidized lipids or 
proteins. During the redox reactions, GSH and TrxSH become oxidized to GSSG 
and thioredoxin disulfide (TrxS2). Both GSSG and TrxS2 are reduced back by GR 
and TrxR, respectively. GSH is also synthesized in a pathway involving c-glutamyl-
cysteinyl ligase (cGCL) and glutathione synthetase (GSH synt). NADPH is recycled 
by the pentose phosphate pathway under enzymes glucose-6-phosphate dehydroge-
nase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD)[71].
4.5.2 Leishmania implementation and oxidative stress
Leishmaniosis are group of parasitic of neglected tropical diseases endemic in 98 
countries. Leishmania spp. are intracellular parasitic protozoa with a complex dige-
netic life cycle requiring a susceptible vertebrate host and a permissive phlebotomus 
insect vector, which allow their transmission. The disease manifestations are from 
self-healing cutaneous lesion to visceral pathology depending on complex interac-
tions between the parasite and the host immune system. The parasite Leishmania 
use Trojan horse strategy when it is transmitted into the circulation system of the 
mammals after the vector sandfly blood meal. The promastigote motile form is 
phagocytized by macrophages and subsequently transform into the nonmotile 
amastigote form. The obligatory intracellular amastigotes reside within phagolyso-
somal vacuoles and adopt sophisticated mechanisms that enable them to avoid the 
hostile defense system of their host organism. The interplay between the parasite 
and its host is a complex process, in which the paramount interest of the parasite is 
to restrict the immune and microbicidal activities of the macrophage, while keeping 
it alive as a nutritional Source [72].
Phagocytosis of microbes leads to a burst of O2
•− production through activation 
of NADPH oxidase [73, 74]. Once inside the host cell, ROS and RNS are the cellular 
major arms against Leishmania. NO is synthesized by nitricoxide synthase (NOS) 
during the conversion of l-arginine to l-citrulline, while O2
•− and other ROS are 
generated by the membrane-bound NADPH-dependent oxidases (NOX) [75].
To deal with this avalanche of oxidative stress molecules and host immune 
response, Leishmania has developed several immune evasion strategies to avoid a 
certain death by oxidative stress. NO production by nitric oxide synthase iNOS is 
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disturbed by highlighting the efficiency of this effect or mechanism. Leishmania 
parasites are particularly efficient at disrupting signals that lead to the activation 
and differentiation of CD4+ Th1cells, such as IL-12 and CD40 signaling [76, 77]. 
Leishmania does not express GSH/GR, but its redox metabolism relies on the gluta-
thione conjugate N1,N8-bis(L-γ-glutamyl-L-hemicystinylglycyl) spermidine, also 
known as trypanothione (T(SH)2). Trypanothione disulfide (TS2) is generated 
when T(SH)2 reduces ROS [78]. Trypanothione reductase (TRs) have structural 
analogies with GRs and are also members of the NADPH-dependent flavoprotein 
oxidoreductase family. TR uses NADPH as an electron donor for the reduction of 
T(S)2 [77, 79].
Leishmania does not express catalase and classical selenium-containing glu-
tathione peroxidases, two major hydroperoxide-eliminating enzymes generally 
present in eukaryotes (Krauth-Siegel & comini, 2008). Instead, these organisms’ 
hydroperoxide metabolism was found to depend on tryparedoxin (TXN) and 
peroxiredoxin (PRX) belonging to the peroxiredoxin family of enzymes and 
are pivotal for T(SH)2 to reduce H2O2 [80, 81]. Overexpression of peroxidases 
in Leishmania demonstrated its protective action against oxidative stress, ROS-
induced programmed cell death, and protein damage [82, 83]. The combined 
hydroperoxide and ONOO- metabolizing activities of 2-Cys peroxiredoxins are also 
likely to account for the increased infectivity of Leishmania mutants overexpress-
ing a cytosolic peroxiredoxin, in an ex vivo model of infection [84].
5. Conclusion
The moderate and controlled production of ROS can lead to a reversible oxida-
tion of the surrounding molecules: the ROS then act as true second messengers. 
Conversely, an overproduction of ROS or a deficit in defense systems leads to the 
appearance of stress which causes a non-specific and irreversible oxidation of 
biological molecules, leading to a loss of function [4]. In addition, it is obvious to 
emphasize that individuals do not have the same antioxidant potential depending 
on their eating habits, their lifestyle, their genetic characteristics or the environ-
ment in which they live. As a result, the antioxidant defense may be different 
from one individual to another. In order to counter the ROS attack and adjust the 
redox balance, a repair process is set up for each pathological situation. As a result, 
endogenous defense induces several signaling mechanisms to adapt to the new 
physiological situation.
Conflict of interest




ALS Amyotrophic Lateral Sclerosis
















HDL High Density Lipoprotein
iNOS nitric oxide synthase
LDL low density lipoprotein













ROS reactive oxygenated species





T1D Type 1 diabetes
TP53 tumor protein 53
TRs trypanothione reductase
TRs trypanothione reductase
Trx ox oxidized thioredoxin





β cells beta cells




1 Department of Cellular Biology and Physiology, Faculty of Nature and Life,  
Saad Dahlab University, Blida, Algeria
2 Structural Bioinformatics, Molecular Modeling and Drug Design, Bioinformatics 
Laboratory, Applied Microbiology and Biomolecules, M’Hamed Bougara 
University, Boumerdes, Algeria
3 Department of Parasitology, Laboratory of Parasitic Eco-epidemiology and 
Population Genetics, Institute Pasteur of Algeria, Route du petit Staoueli, Algiers, 
Algeria
*Address all correspondence to: aeddaikra@yahoo.fr
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
13
Endogenous Enzymatic Antioxidant Defense and Pathologies
DOI: http://dx.doi.org/10.5772/intechopen.95504
References
[1] Migdal C, Serres M. Espèces 
réactives de l’oxygène et stress oxydant. 
Medecine/Sciences 2011;27:405-412.
[2] Sies H. Hydrogen peroxide as a 
central redox signaling molecule 
in physiological oxidative stress: 
Oxidative eustress. Redox Biol 
2017;11:613-619.
[3] Kim TH, Hong JM, Oh B,  
et al. Genetic association study of 
polymorphisms in the catalase gene 
with the risk of osteonecrosis of the 
femoral head in the Korean population. 
Osteoarthr Cartil 2008;16:1060-1066.
[4] Carrière A, Galinier A, Fernandez Y, 
et al. Les espèces actives de l’oxygène: 
Le yin et le yang de la mitochondrie. 
Medecine/Sciences 2006;22:47-53.
[5] Amir Aslani B, Ghobadi S. Studies on 
oxidants and antioxidants with a brief 
glance at their relevance to the immune 
system. Life Sci 2016;146:163-173.
[6] Beaudeux J-L, Peynet J, 
Bonnefont-Rousselot D, et al. Cellular 
sources of reactive oxygen and 
nitrogen species. Roles in signal 
transcription pathways. Ann Pharm Fr 
2006;64:373-381.
[7] Favier A. Stress oxydant Stress 
oxydant et pathologies humaines. Ann 
Pharm Fr 2006;64:390-396.
[8] Goudable J, Favier A. Radicaux libres 
oxygénés et antioxydants. Nutr Clin 
Métabolisme 1997;11:115-120.
[9] Haleng et al. Le stress oxydant. no 
date;
[10] Gardès-Albert M, Bonnefont- 
Rousselot D, Abedinzadeh Z, et 
al. Espèces réactives de l’oxygène. 
Comment l’oxygène peut-il devenir 
toxique? Actual Chim 2003;269:91-96.
[11] Alfonso-Prieto M, Biarnés X,  
Vidossich P, et al. The Molecular 
Mechanism of the Catalase Reaction. J 
Am Chem Soc 2009;131:11751-11761.
[12] Leverve X. Stress oxydant 
et antioxydants? Cah Nutr Diet 
2009;44:219-224.
[13] Forman HJ, Maiorino M, Ursini F. 
Signaling functions of reactive oxygen 
species. Biochemistry 
2010;49:835-842.
[14] Angelova PR, Abramov AY. Role of 
mitochondrial ROS in the brain: from 
physiology to neurodegeneration. FEBS 
Lett 2018;592:692-702.
[15] Echtay KS, Esteves TC, Pakay JL, 
et al. A signalling role for 4-hydroxy-2-
nonenal in regulation of mitochondrial 
uncoupling. EMBO J 2003;22:4103-10.
[16] Candas D, Li JJ. MnSOD in oxidative 
stress response-potential regulation via 
mitochondrial protein influx. Antioxid 
Redox Signal 2014;20:1599-617.
[17] Chistiakov AD, Savost’anov K 
V., Turakulov RI, et al. A new type 1 
diabetes susceptibility locus containing 
the catalase gene (chromosome 11p13) 
in a Russian population. Diabetes Metab 
Res Rev 2004;20:219-224.
[18] Miao L, St Clair DK. Regulation 
of superoxide dismutase genes: 
implications in disease. Free Radic Biol 
Med 2009;47:344-56.
[19] Bresciani G, Cruz IBM, De 
Paz JA, et al. The MnSOD Ala16Val 
SNP: Relevance to human diseases and 
interaction with environmental factors. 
Free Radic Res 2013;47:781-792.
[20] Banks CJ, Andersen JL. Mechanisms 
of SOD1 regulation by post-
translational modifications. Redox Biol 
2019;26:101270.
Antioxidants - Benefits, Sources, Mechanisms of Action
14
[21] Zelko IN, Mariani TJ, Folz RJ. 
Superoxide dismutase multigene family: 
A comparison of the CuZn-SOD 
(SOD1), Mn-SOD (SOD2), and 
EC-SOD (SOD3) gene structures, 
evolution, and expression. Free Radic 
Biol Med 2002;33:337-349.
[22] Ogata M, Mizugaki J. Properties of 
Residual Catalase in the Erythroeytes 
of Japanese-Type Acatalasemia. 
1979;338:329-338.
[23] Kodydková J, Vávrová L, Kocík M, et 
al. Human catalase, its polymorphisms, 
regulation and changes of Its activity 
in different diseases. Folia Biol (Czech 
Republic) 2014;60:153-167.
[24] Ahn J, Nowell S, McCann SE, 
et al. Associations between catalase 
phenotype and genotype: Modification 
by epidemiologic factors. Cancer 
Epidemiol Biomarkers Prev 
2006;15:1217-1222.
[25] Kang DH, Kang SW. Targeting 
cellular antioxidant enzymes for 
treating atherosclerotic vascular disease. 
Biomol Ther 2013;21:89-96.
[26] Toppo S, Flohé L, Ursini F, et al. 
Catalytic mechanisms and specificities 
of glutathione peroxidases: Variations of 
a basic scheme. Biochim Biophys Acta - 
Gen Subj 2009;1790:1486-1500.
[27] Ursini F, Maiorino M, 
Forman HJ. Redox homeostasis: The 
Golden Mean of healthy living. Redox 
Biol 2016;8:205-215.
[28] Lubos E, Kelly NJ, Oldebeken SR, et 
al. Glutathione peroxidase-1 deficiency 
augments proinflammatory cytokine-
induced redox signaling and human 
endothelial cell activation. J Biol Chem 
2011;286:35407-35417.
[29] Bacchetti T, Ferretti G, Sahebkar A. 
The role of paraoxonase in cancer. 
Semin Cancer Biol 2019;56:72-86.
[30] Primo-Parmo SL, Sorenson RC,  
Teiber J, et al. The human serum 
paraoxonase/arylesterase gene (PON1) 
is one member of a multigene family. 
Genomics 1996;33:498-507.
[31] Devarajan A, Shih D, Reddy ST. 
Inflammation, infection, cancer and all 
that...the role of paraoxonases. Adv Exp 
Med Biol 2014;824:33-41.
[32] Heppell-Parton A, Cahn A, 
Bench A, et al. Thioredoxin, a mediator 
of growth inhibition, maps to 9q31. 
Genomics 1995;26:379-381.
[33] Lee S, Kim SM, Lee RT. Thioredoxin 
and thioredoxin target proteins: From 
molecular mechanisms to functional 
significance. Antioxidants Redox Signal 
2013;18:1165-1207.
[34] Matsuzawa A. Thioredoxin and 
redox signaling: Roles of the thioredoxin 
system in control of cell fate. Arch 
Biochem Biophys 2017;617:101-105.
[35] Golden TR, Patel M. Catalytic 
Antioxidants and Neurodegeneration. 
2009;11:.
[36] Dias V, Junn E, Mouradian MM.  
The role of oxidative stress in 
parkinson’s disease. J Parkinsons Dis 
2013;3:461-491.
[37] Percário S, Da Silva Barbosa A, 
Varela ELP, et al. Oxidative Stress in 
Parkinson’s Disease: Potential Benefits 
of Antioxidant Supplementation. Oxid 
Med Cell Longev 2020;2020:.
[38] Zhou C, Huang Y, Przedborski S. 
Oxidative stress in Parkinson’s disease: 
A mechanism of pathogenic and 
therapeutic significance. Ann N Y Acad 
Sci 2008;1147:93-104.
[39] Trist BG, Hare DJ, Double KL. 
Oxidative stress in the aging substantia 
nigra and the etiology of Parkinson’s 
disease. Aging Cell 2019;18:.
15
Endogenous Enzymatic Antioxidant Defense and Pathologies
DOI: http://dx.doi.org/10.5772/intechopen.95504
[40] Bowling AC, Beal MF. 
Bioenergetic and oxidative stress in 
neurodegenerative diseases. Life Sci 
1995;56:1151-1171.
[41] Schapira AHV, Cooper JM, 
Dexter D, et al. Mitochondrial Complex 
I Deficiency in Parkinson’s Disease. J 
Neurochem 1990;54:823-827.
[42] Cheignon C, Tomas M, 
Bonnefont-Rousselot D, et al. Oxidative 
stress and the amyloid beta peptide 
in Alzheimer’s disease. Redox Biol 
2018;14:450-464.
[43] Casado Á, Encarnación 
López-Fernández M, Concepción 
Casado M, et al. Lipid peroxidation 
and antioxidant enzyme activities in 
vascular and alzheimer dementias. 
Neurochem Res 2008;33:450-458.
[44] Di Domenico F, Pupo G, 
Giraldo E, et al. Oxidative signature 
of cerebrospinal fluid from mild 
cognitive impairment and Alzheimer 
disease patients. Free Radic Biol Med 
2016;91:1-9.
[45] Morel Y, Barouki R. Influence du 
stress oxydant sur la régulation des 
gènes. Médecine/Sciences 1998;14:713.
[46] Ramani S, Pathak A, Dalal V, et 
al. Oxidative Stress in Autoimmune 
Diseases: An Under Dealt Malice. Curr 
Protein Pept Sci 2020;21:611-621.
[47] Barcala Tabarrozzi AE, 
Castro CN, Dewey RA, et al. Cell-based 
interventions to halt autoimmunity 
in type 1 diabetes mellitus. Clin Exp 
Immunol 2013;171:135-146.
[48] Cabrera SM, Chen Y-G, 
Hagopian WA, et al. Blood-based 
signatures in type 1 diabetes. 
Diabetologia 2016;59:414-25.
[49] Bluestone JA, Herold K, 
Eisenbarth G. Genetics, pathogenesis 
and clinical interventions in type 1 
diabetes. Nature 2010;464:1293-300.
[50] Castro-Correia C, Maia ML, 
Norberto S, et al. Can Antioxidative 
Status Be Involved in Type 1 Diabetes? J 
Clin Med Res 2017;9:998-1001.
[51] Pradeep DCD, Vegi K, Kutty AVM. 
Protein carbonyl content as a stable 
Oxidative stress marker in Type 
II Diabetes . Int J Biol Med Res 
2012;3:2362-2365.
[52] Padgett LE, Broniowska KA, 
Hansen PA, et al. The role of reactive 
oxygen species and proinflammatory 
cytokines in type 1 diabetes 
pathogenesis. Ann N Y Acad Sci 
2013;1281:16-35.
[53] Eddaikra A, Amroun H, Raache R, 
et al. Clinical variables and ethnicity 
may influenced by polymorphism of 
CAT −262C/T and MnSOD 47C/T 
antioxidant enzymes in Algerian type1 
diabetes without complications. Gene 
2018;670:182-192.
[54] Eddaikra A, Touil Boukoffa C.  
Polymorphism of MnSOD 47C/T 
antioxidant enzymes and type 1 
diabetes. In: Diabetes. Elsevier; 2020. p. 
107-115.
[55] Bonnefont-Rousselot D, 
Peynet J, Beaudeux JL, et al. Stress 
oxydant, fonctions vasculaires et 
athérosclérose. Nutr Clin Metab 
2002;16:260-267.
[56] Góth L, Nagy T. Inherited catalase 
deficiency: Is it benign or a factor in 
various age related disorders? Mutat 
Res - Rev Mutat Res 2013;753:147-154.
[57] Sullivan LB, Chandel NS. 
Mitochondrial reactive oxygen species 
and cancer. Cancer Metab 2014;2:.
[58] Bacchetti T, Sartini D, Pozzi V, et al. 
Exploring the role of Paraoxonase-2 in 
Antioxidants - Benefits, Sources, Mechanisms of Action
16
bladder cancer: Analyses performed on 
tissue samples, urines and cell cultures. 
Oncotarget 2017;8:28785-28795.
[59] Utanğaç MM, Yeni E, Savaş M, et 
al. Mesane kanserinde paraoksanaz ve 
arilesteraz aktivitesi. Turk Urol Derg 
2017;43:147-151.
[60] Huang D, Wang Y, He Y, et al. 
Paraoxonase 3 is involved in the multi-
drug resistance of esophageal cancer 
11 Medical and Health Sciences 1112 
Oncology and Carcinogenesis. Cancer 
Cell Int 2018;18:1-11.
[61] Sznarkowska A, Kostecka A, 
Meller K, et al. Inhibition of cancer 
antioxidant defense by natural 
compounds. Oncotarget 
2017;8:15996-16016.
[62] Ahmed Amar SA, Eryilmaz R,  
Demir H, et al. Determination of 
oxidative stress levels and some 
antioxidant enzyme activities in prostate 
cancer. Aging Male 2019;22:198-206.
[63] Kangari P, Farahany TZ, Golchin A, 
et al. Enzymatic antioxidant and lipid 
peroxidation evaluation in the newly 
diagnosed breast cancer patients 
in Iran. Asian Pacific J Cancer Prev 
2018;19:3511-3515.
[64] Galleze A, Kocyigit A, Cherif N, 
et al. Assessment of oxidative/anti-
oxidative markers and DNA damage 
profile induced by chemotherapy in 
algerian children with lymphoma. Drug 
Chem Toxicol 2020;43:169-173.
[65] Glorieux C, Calderon PB. Catalase, 
a remarkable enzyme: Targeting the 
oldest antioxidant enzyme to find a new 
cancer treatment approach. Biol Chem 
2017;398:1095-1108.
[66] Alvar J, Vélez ID, Bern C, et al. 
Leishmaniasis worldwide and global 
estimates of its incidence. PLoS One 
2012;7:.
[67] Geneva: World Health 
Organization. World malaria report 
2019. 2019.
[68] Percário S, Moreira DR, 
Gomes BAQ, et al. Oxidative stress 
in Malaria. Int J Mol Sci 
2012;13:16346-16372.
[69] Cowman AF, Healer J, Marapana D, 
et al. Malaria: Biology and Disease. Cell 
2016;167:610-624.
[70] Postma NS, Mommers EC, 
Eling WMC, et al. Oxidative stress in 
malaria; implications for prevention 
and therapy. Pharm World Sci 
1996;18:121-129.
[71] Kavishe RA, Koenderink JB, 
Alifrangis M. Oxidative stress in 
malaria and artemisinin combination 
therapy: Pros and Cons. FEBS J 
2017;284:2579-2591.
[72] Shapira M, Zinoviev A. Leishmania 
parasites act as a Trojan horse that 
paralyzes the translation system of 
host macrophages. Cell Host Microbe 
2011;9:257-259.
[73] Babior BM. Phagocytes 
and oxidative stress. Am J Med 
2000;109:33-44.
[74] Minakami R, Sumimoto H. 
Phagocytosis-coupled activation of 
the superoxide-producing phagocyte 
oxidase, a member of the NADPH 
oxidase (Nox) family. Int J Hematol 
2006;84:193-198.
[75] Cecílio P, Pérez-Cabezas B, 
Santarém N, et al. Deception and 
manipulation: The arms of Leishmania, 
a successful parasite. Front Immunol 
2014;5:1-16.
[76] Mougneau E, Bihl F,  
Glaichenhaus N. Cell biology and 
immunology of Leishmania. Immunol 
Rev 2011;240:286-296.
17
Endogenous Enzymatic Antioxidant Defense and Pathologies
DOI: http://dx.doi.org/10.5772/intechopen.95504
[77] Olekhnovitch R, Bousso P. 
Induction, Propagation, and Activity 
of Host Nitric Oxide: Lessons from 
Leishmania Infection. Trends Parasitol 
2015;31:653-664.
[78] Van Assche T, Deschacht M, Da 
Luz RAI, et al. Leishmania-macrophage 
interactions: Insights into the 
redox biology. Free Radic Biol Med 
2011;51:337-351.
[79] Krauth-siegel RL, Enders B, 
Henderson GB, et al. Trypanothione 
reductase from. 1987;128:123-128.
[80] Castro H, Tomás AM. Peroxidases 
of trypanosomatids. Antioxidants 
Redox Signal 2008;10:1593-1606.
[81] Romao S, Castro H, Sousa C, 
et al. The cytosolic tryparedoxin of 
Leishmania infantum is essential 
for parasite survival. Int J Parasitol 
2009;39:703-711.
[82] Dolai S, Yadav RK, Pal S, et al. 
Leishmania major ascorbate peroxidase 
overexpression protects cells against 
reactive oxygen species-mediated 
cardiolipin oxidation. Free Radic Biol 
Med 2008;45:1520-1529.
[83] Dolai S, Yadav RK, Pal S, et al. 
Overexpression of mitochondrial 
Leishmania major ascorbate peroxidase 
enhances tolerance to oxidative 
stress-induced programmed cell death 
and protein damage. Eukaryot Cell 
2009;8:1721-1731.
[84] Barr SD, Gedamu L. Role of 
peroxidoxins in Leishmania chagasi 
survival. Evidence of an enzymatic 
defense against nitrosative stress. J Biol 
Chem 2003;278:10816-10823.
